Difference between revisions of "Selumetinib (Koselugo)"
Jump to navigation
Jump to search
m |
m |
||
Line 6: | Line 6: | ||
===[[Ovarian cancer]]=== | ===[[Ovarian cancer]]=== | ||
# Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb;14(2):134-40. Epub 2012 Dec 21. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627419/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/23261356 PubMed] | # Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb;14(2):134-40. Epub 2012 Dec 21. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627419/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/23261356 PubMed] | ||
+ | |||
+ | ===[[Thyroid cancer]]=== | ||
+ | # Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013 Feb 14;368(7):623-32. [http://www.nejm.org/doi/full/10.1056/NEJMoa1209288 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/23406027 PubMed] | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
Line 15: | Line 18: | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
+ | [[Category:Thyroid cancer medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] |
Revision as of 16:07, 21 September 2016
Mechanism of action
Inhibits the enzyme MAPK kinase (MEK), specifically the MEK1 and MEK2 subtypes of the enzyme.
Preliminary data
Ovarian cancer
- Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb;14(2):134-40. Epub 2012 Dec 21. link to original article PubMed
Thyroid cancer
- Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013 Feb 14;368(7):623-32. link to original article PubMed